Allopurinol

Essential medicine status

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.5. Supportive medicines

EMLc | ATC codes: M04AA01

Indication	Tumour lysis syndrome ICD11 code: 5D01
INN	Allopurinol
Medicine type	Chemical agent
List type	Complementary
Formulations	**Parenteral > General injections > IV:** 500 mg (as sodium) powder for injection (EMLc) **Oral > Solid:** 100 mg (EMLc) ; 300 mg (EMLc)
EML status history	First added in 2007 (TRS 950) Changed in 2025 (TRS 1064)
Sex	All
Age	Children (1 month - 12 years)
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer supportive care
Wikipedia	Allopurinol
DrugBank	Allopurinol

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of allopurinol powder for injection 500 mg to the EMLc for use in the prophylaxis and treatment of tumour lysis syndrome.